{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:56:00Z","timestamp":1768568160933,"version":"3.49.0"},"posted":{"date-parts":[[2025,7,28]]},"group-title":"Endocrinology (including Diabetes Mellitus and Metabolic Disease)","reference-count":39,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,7,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>The new generation of incretin-based therapies are potent anti-obesity medications (AOMs) that offer the first non-surgical treatment for 936 million patients globally suffering from being overweight or obese[1]. However, clinical data suggest that incretin-mimetics could cause a disproportionate decrease in lean body mass (LBM) [2, 3], raising a concern for deterioration of skeletal muscle and acceleration of sarcopenic obesity[4]. Unfortunately, muscle mass and function are not routinely assessed in obesity studies and original data on the matter remains sparse. In this work, we conducted various pre-clinical studies and a proof-of-concept clinical trial to examine how skeletal muscle is affected by AOMs. We found that in mice with diet-induced obesity (DIO), incretin-based therapies result predominantly in a substantial decrease in fat mass alongside a small but significant decrease in LBM. Among the lean tissues, the decrease in liver mass exceeded the change in muscle mass robustly. While absolute muscle mass did decrease, relative muscle mass (i.e., the muscle mass to body weight (BW) ratio) improved significantly. Similarly, we found that absolute muscle strength decreased mildly but increased relative to the BW of mice. The relative preservation of muscle was also associated with marked improvement in running performance. Additionally, during a scenario of extreme muscle wasting (i.e., immobilization), DIO mice on incretin-based therapies did not experience more muscle loss than calorie-matched, pair-fed mice. Finally, in our clinical proof-of-concept trial, patients on AOMs significantly decreased BW, which was accompanied by a mild decrease in absolute LBM but an improvement in relative LBM. Muscle function as indicated by maximum voluntary contraction (MVC) did not decrease. Overall, these data suggest that in middle-aged obese mice and men, incretin-based therapies do cause a mild decrease in absolute muscle mass and strength that is offset by a more pronounced decrease in fat and liver mass, resulting in an improved muscle to BW ratio, function, and mobility.<\/jats:p>","DOI":"10.1101\/2025.07.28.25332295","type":"posted-content","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T23:10:19Z","timestamp":1753744219000},"source":"Crossref","is-referenced-by-count":0,"title":["Pharmacological weight loss with incretin-based therapies does not result in a disproportionate loss of muscle mass or function in obese mice and humans"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1838-4279","authenticated-orcid":false,"given":"Henning Tim","family":"Langer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie K.","family":"Gilmore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris M. T.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Roux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Bariohay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tha\u00efs","family":"Rhouquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manar","family":"Awada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Marcotorchino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorrine","family":"Bournot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Nunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Titchenell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Liskiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timo D.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oluwaseun","family":"Anyiam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Atherton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iskandar","family":"Idris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Haritonow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Norman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"M\u00fcller-Werdan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Baar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2025073009000766000_2025.07.28.25332295v1.1","unstructured":"Federation, W.O. , World Obesity Atlas 2025. London: World Obesity Federation, 2025, 2025."},{"key":"2025073009000766000_2025.07.28.25332295v1.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"2025073009000766000_2025.07.28.25332295v1.3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2206038"},{"key":"2025073009000766000_2025.07.28.25332295v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00272-9"},{"key":"2025073009000766000_2025.07.28.25332295v1.5","doi-asserted-by":"publisher","DOI":"10.1079\/PNS19910055"},{"issue":"3","key":"2025073009000766000_2025.07.28.25332295v1.6","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41587-024-02176-5","article-title":"After obesity drugs\u2019 success, companies rush to preserve skeletal muscle","volume":"42","year":"2024","journal-title":"Nat Biotechnol"},{"issue":"11","key":"2025073009000766000_2025.07.28.25332295v1.7","doi-asserted-by":"crossref","first-page":"bvae164","DOI":"10.1210\/jendso\/bvae164","article-title":"Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA Treatments","volume":"8","year":"2024","journal-title":"J Endocr Soc"},{"key":"2025073009000766000_2025.07.28.25332295v1.8","doi-asserted-by":"crossref","unstructured":"Sattar, N. , et al., Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. 2025.","DOI":"10.1016\/S2213-8587(25)00027-0"},{"key":"2025073009000766000_2025.07.28.25332295v1.9","doi-asserted-by":"crossref","first-page":"101880","DOI":"10.1016\/j.molmet.2024.101880","article-title":"Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism","volume":"80","year":"2024","journal-title":"Mol Metab"},{"key":"2025073009000766000_2025.07.28.25332295v1.10","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2147\/DMSO.S425642","article-title":"GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway","volume":"16","year":"2023","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2025073009000766000_2025.07.28.25332295v1.11","doi-asserted-by":"crossref","first-page":"101533","DOI":"10.1016\/j.molmet.2022.101533","article-title":"Next generation GLP-1\/GIP\/glucagon triple agonists normalize body weight in obese mice","volume":"63","year":"2022","journal-title":"Mol Metab"},{"issue":"9","key":"2025073009000766000_2025.07.28.25332295v1.12","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity","volume":"184","year":"2024","journal-title":"JAMA Intern Med"},{"key":"2025073009000766000_2025.07.28.25332295v1.13","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.00703.2016"},{"key":"2025073009000766000_2025.07.28.25332295v1.14","doi-asserted-by":"publisher","DOI":"10.1111\/apha.12190"},{"key":"2025073009000766000_2025.07.28.25332295v1.15","doi-asserted-by":"crossref","unstructured":"Wall, B.T. , M.L. Dirks , and L.J.C. van Loon , Skeletal muscle atrophy during short-term disuse: implications for age-related sarcopenia. Ageing research reviews, 2013.","DOI":"10.1016\/j.arr.2013.07.003"},{"issue":"12","key":"2025073009000766000_2025.07.28.25332295v1.16","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1002\/jor.25313","article-title":"A novel mouse model of hindlimb joint contracture with 3D-printed casts","volume":"40","year":"2022","journal-title":"J Orthop Res"},{"key":"2025073009000766000_2025.07.28.25332295v1.17","doi-asserted-by":"crossref","first-page":"101633","DOI":"10.1016\/j.molmet.2022.101633","article-title":"BI 45CS0C: Discovery and preclinical pharmacology of a novel GCGR\/GLP-1R dual agonist with robust anti-obesity efficacy","volume":"66","year":"2022","journal-title":"Mol Metab"},{"key":"2025073009000766000_2025.07.28.25332295v1.18","doi-asserted-by":"crossref","first-page":"110779","DOI":"10.1016\/j.diabres.2023.110779","article-title":"Perspectives in weight control in diabetes - Survodutide","volume":"207","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"2025073009000766000_2025.07.28.25332295v1.19","doi-asserted-by":"publisher","DOI":"10.1042\/bj2280575"},{"issue":"8","key":"2025073009000766000_2025.07.28.25332295v1.20","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.2337\/db22-0079","article-title":"The Effect of Glucagon on Protein Catabolism During Insulin Deficiency: Exchange of Amino Acids Across Skeletal Muscle and the Splanchnic Bed","volume":"71","year":"2022","journal-title":"Diabetes"},{"issue":"3","key":"2025073009000766000_2025.07.28.25332295v1.21","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s42255-021-00369-9","article-title":"Liver alanine catabolism promotes skeletal muscle atrophy and hyperglycaemia in type 2 diabetes","volume":"3","year":"2021","journal-title":"Nat Metab"},{"issue":"6","key":"2025073009000766000_2025.07.28.25332295v1.22","first-page":"514","article-title":"Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial","volume":"38G","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"2025073009000766000_2025.07.28.25332295v1.23","first-page":"311","article-title":"A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis","volume":"3G1","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"2025073009000766000_2025.07.28.25332295v1.24","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.clnu.2024.06.034","article-title":"Metabolic effects of very-low calorie diet, Semaglutide, or combination of the two, in individuals with type 2 diabetes mellitus","volume":"43","year":"2024","journal-title":"Clin Nutr"},{"issue":"5","key":"2025073009000766000_2025.07.28.25332295v1.25","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1111\/dom.16275","article-title":"Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight","volume":"27","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"2025073009000766000_2025.07.28.25332295v1.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59485-9"},{"issue":"3","key":"2025073009000766000_2025.07.28.25332295v1.27","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1249\/MSS.0000000000001448","article-title":"Associations of Muscle Mass and Strength with All-Cause Mortality among US Older Adults","volume":"50","year":"2018","journal-title":"Med Sci Sports Exerc"},{"key":"2025073009000766000_2025.07.28.25332295v1.28","unstructured":"Langer, H.T. , et al., Commentaries on viewpoint: rejuvenation of the term sarcopenia. 2019."},{"key":"2025073009000766000_2025.07.28.25332295v1.29","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/61.10.1059"},{"issue":"17","key":"2025073009000766000_2025.07.28.25332295v1.30","first-page":"1573","article-title":"Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis","volume":"3G1","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"2025073009000766000_2025.07.28.25332295v1.31","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/cid\/ciae384","article-title":"Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study","volume":"80","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2025073009000766000_2025.07.28.25332295v1.32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.6586"},{"key":"2025073009000766000_2025.07.28.25332295v1.33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03018-2"},{"key":"2025073009000766000_2025.07.28.25332295v1.34","doi-asserted-by":"crossref","unstructured":"Golub, L.S. , et al., The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial. Nutr Metab Cardiovasc Dis, 2025: p. 104036.","DOI":"10.1016\/j.numecd.2025.104036"},{"issue":"8","key":"2025073009000766000_2025.07.28.25332295v1.35","first-page":"860","article-title":"Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes","volume":"30","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"2025073009000766000_2025.07.28.25332295v1.36","unstructured":"Keys, A. , et al., The biology of human starvation. (2 Vols). 1950: University of Minnesota Press."},{"issue":"3","key":"2025073009000766000_2025.07.28.25332295v1.37","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/dom.15400","article-title":"Impact of weight loss and weight gain trajectories on body composition in a population at high risk of type 2 diabetes: A prospective cohort analysis","volume":"26","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"2025073009000766000_2025.07.28.25332295v1.38","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/jor.25116","article-title":"Sex differences in systemic bone and muscle loss following femur fracture in mice","volume":"40","year":"2022","journal-title":"Journal of Orthopaedic Research\u00ae"},{"issue":"9","key":"2025073009000766000_2025.07.28.25332295v1.39","doi-asserted-by":"crossref","first-page":"e21860","DOI":"10.1096\/fj.202100711RR","article-title":"A mutation in desmin makes skeletal muscle less vulnerable to acute muscle damage after eccentric loading in rats","volume":"35","year":"2021","journal-title":"The FASEB Journal"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.07.28.25332295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:41:42Z","timestamp":1768509702000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.07.28.25332295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":39,"URL":"https:\/\/doi.org\/10.1101\/2025.07.28.25332295","relation":{},"subject":[],"published":{"date-parts":[[2025,7,28]]},"subtype":"preprint"}}